NAVIGATOR: Tezepelumab Could Transform Severe Uncontrolled Asthma Care
AstraZeneca/Amgen's Positive Top-Line Phase III Results
In top-line results from the Phase III NAVIGATOR study, AstraZeneca/Amgen’s human monoclonal antibody tezepelumab has significantly reduced disease exacerbations in patients with severe asthma regardless of their type of inflammation, including those with low eosinophil counts.
